Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Citations 0
December 22/29, 1999

Safety of FDA-Approved Drugs

Author Affiliations

Phil B.FontanarosaMD, Interim CoeditorIndividualAuthorMargaret A.WinkerMD, Deputy EditorIndividualAuthorStephenLurieMD PhD, Fishbein FellowIndividualAuthor


Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999

JAMA. 1999;282(24):2297-2298. doi:10.1001/jama.282.24.2297

To the Editor: Dr Friedman and colleagues1 downplayed serious safety questions about dexfenfluramine, mibefradil, and bromfenac sodium, which were approved in 1996-1997 and subsequently removed from the market, that were raised prior to marketing. Furthermore, Friedman et al failed to acknowledge that these drugs did not represent significant advances over the numerous approved drugs in their therapeutic categories.

First Page Preview View Large
First page PDF preview
First page PDF preview